Table 1.

The effect of BMS-345541 on the expression and phosphorylation of cytosolic IκB-α and expression of nuclear p65

Treatment	Cytosolic IκB-α/GAPDH	Proportion of Cytosolic Phosphorylated IκB-α	Nuclear p65/Oct1
Vehicle	0.92 ± 0.09, N = 7	0.55 ± 0.07, N = 4	0.26 ± 0.09, N = 7
1 uM BMS345541	0.74 ± 0.11, N = 7	0.68 ± 0.06, N = 4	0.46 ± 0.11, N = 7
Vehicle	1.765 ± 0.47, N = 4	0.35 ± 0.9, N = 4	0.39 ± 0.05, N = 20
10 uM BMS345541	1.16 ± 0.20, N = 4	0.48 ± 0.08, N = 4	0.47 ± 0.08, N = 20
Vehicle	1.39 ± 0.08, N = 12	---------	1.20 ± 0.08, N = 6
50 uM BMS345541	1.1 ± 0.12, N = 13	---------	1.12 ± 0.08, N = 7

Shown are the means ± SEM and N values for densitometric results obtained from the appropriate cell extracts of hemidiaphragm exposed to either vehicle or the indicated concentrations of BMS-345541. N represents the number of costal hemidiaphragms used to obtain the densitometric measurements from Western blots of the appropriate protein, using GAPDH as a loading control for cytosolic extracts and Oct 1 as a loading control for nuclear extracts. Separate vehicle controls were used for each concentration of BMS-345541 analyzed. BMS-345541 did not significantly influence cytosolic IκB-α expression, the proportion of phosphorylated IκB-α in the cytosol, or the nuclear expression of p65 at any concentration (1, 10, 50 μM).